Conditions: Healthy Volunteers
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 30
Healthy volunteers: yes

Brief summary:
This is a phase I study of LY3023703 in healthy participants. The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it when given to humans. Information about any side effects that may occur will also be collected. Participants will remain in the study for approximately 3 months. This study is for research purposes only and is not intended to treat any medical condition.

Detailed description:

Arms:
arm 1: Single dose of placebo administered orally on up to one occasion separated by at least a 3 week wash out period. arm 2: Up to 6 single escalating doses of LY3023703 \[0.1 milligram (mg) up to 60 mg\] administered orally on up to two occasions per participant separated by at least a 3 week wash out period. arm 3: Positive control. Single 400 mg dose of celecoxib administered orally, open label, on one occasion separated by at least a 3 week washout period.

Interventions: intervention 1: LY3023703 intervention 2: Placebo intervention 3: Celecoxib
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally intervention 3: Administered orally

Protocol document: